NCT00352378View on ClinicalTrials.gov

Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

209

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

October 31, 2005

Study Completion Date

January 31, 2006

Conditions

Breast Cancer

Interventions

DRUG

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine

"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"

All Listed Sponsors

lead

National Cancer Center, Korea

OTHER_GOV

NCT00352378 - Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer | Biotech Hunter | Biotech Hunter